Abbott Laboratories has posted a strong set of financials for the third quarter, helped by a one-time gain and the continuing revenue rise for Humira.

Net income leapt 36.5% to $1.48 billion, due in part to a $287 million gain from a settlement with Medtronic concerning stent technology. Group sales were up 3.5% to $7.76 billion and adjusting for the negative effect of foreign exchange, the increase would have been 8.4%.

Worldwide pharmaceutical sales slipped 1.6% to $4.06 billion, again due to currency effects, but the anti-inflammatory blockbuster Humira (adalimumab), which is approved for indications covering rheumatoid arthritis, Crohn’s disease and psoriasis, soared once more. Sales of the drug shot up 23.8% to $1.49 billion and Abbott said that underlying demand for Humira remains strong across all three indications.

As for the company’s lipids franchise, TriCor (fenofibrate) and the recently-approved TriLipix (fenofibric acid) contributed $330 million, down 1.1%, while Niaspan (niacin) brought in $215 million, a rise of 10.6%. Of Abbott’s other products, sales of Depakote (divalproex sodium) for manic episodes, migraines and several types of epileptic disorders, were battered by generic competition and fell 70.9% to $92 million.

The prostate cancer therapy Lupron (leuprolide) fell 11.5% to $195 million, while revenues from the HIV drug Kaletra (lopinavir/ritonavir) were down 8.7% to $353 million. Sales of the hypothyroid medication Synthroid (levothyroxine) were up 3.7% to $134 million.

Miles White, Abbott chief executive, said that the firm is performing well, having generated higher-than-expected earnings growth in the third quarter. He noted that the quarter also saw a series acquisitions, including the purchase of Solvay Pharmaceuticals. These deals “add to our diverse mix of global businesses, with new technologies, established products and emerging market infrastructure that will help us deliver sustainable industry-leading growth”, he added.